Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

SECTION EDITOR'S NOTE: Metastatic colorectal cancer is the second leading cause of cancer death in the United States. Since 1995, treatment regimens have included capecitabine, irinotecan, oxaliplatin, bevacizumab, cetuximab, panitumumab, aflibercept, and reforafenib. These medications have dou...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Díaz-Rubio, Eduardo, Pietrantonio, Filippo, de Braud, Filippo
Format: Artigo
Langue:Inglês
Publié: AlphaMed Press 2012
Sujets:
Challenging Cases
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500363/
https://ncbi.nlm.nih.gov/pubmed/23073991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0075
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires